BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Drug Development

  Alzheimer’s Drug Discovery Foundation Comment On TRAILBLAZER-ALZ Results

  Eli Lilly and Company presented detailed results of its phase 2 TRAILBLAZER-ALZ study , showing that its investigational drug donanemab met its primary endpoint, slowing decline in a combined measure of cognition and daily function by 32% in patients with symptomatic early-stage Alzheimer’s disease.

  March 13, 2021

   · 

  4 min read
• Policy

  Statement from the Chief Public Health Officer of Canada on March 13, 2021

  The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

  March 13, 2021

   · 

  5 min read
• Drug Development

  Lilly’s donanemab slowed Alzheimer’s disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM

  Findings from the primary endpoint supported by consistency of all secondary outcome measures assessing cognition and function

  March 13, 2021

   · 

  9 min read